Abstract
The first chapter includes a systematic review that aims to examine the effectiveness of using digital cognitive assessments to assess Parkinson’s Disease Mild Cognitive Impairment (PD-MCI).The second chapter (Phase I) includes the development of a novel cognitive test, Mater-Royal Parkinson’s Disease Cognitive Scale (M-R PDCS). The objectives were to continue to develop, validate, refine, and externally validate a novel cognitive screening instrument to differentiate normal cognition from Parkinson’s Disease Mild Cognitive Impairment (PD-MCI). Using mixed methods, 20 experts within the field of PD-MCI reviewed the validity and acceptability of the M-R PDCS. The results and implications of Phase I informed recommendations for future research.
Chapter 3 (Phase II) extends on from Phase I, further aiming to validate the M-R PDCS by collecting normative data (from people who do not have PD). A cross-sectional, quantitative method of design recruited 100 adults, who completed both the digital M-R PDCS and a digital version of the Addenbrooke’s (ACE-III) cognitive test. Aspects of reliability were also examined. The results and implications of these are discussed with recommendations for future research.
Thesis is embargoed until 31 December 2026.
| Date of Award | Dec 2024 |
|---|---|
| Original language | English |
| Awarding Institution |
|
| Sponsors | Business Services Organisation |
| Supervisor | Martin Dempster (Supervisor), David Curran (Supervisor) & Nigel Lyttle (Supervisor) |
Keywords
- Parkinson’s disease
- PD
- mild cognitive impairment
- MCI
- neuropsychological cognitive testing
- digital methods
Cite this
- Standard